Literature DB >> 8204668

Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma.

Z Ying1, H Tojo, T Komatsubara, M Nakagawa, M Inada, S Kawata, Y Matsuzawa, M Okamoto.   

Abstract

Enzyme activity, protein contents, and mRNA contents of group II phospholipase A2 (PLA2) in hepatocellular carcinoma (HCC) surgically obtained from 8 patients were compared with those in either its neighboring liver tissues or control liver tissues. The PLA2 specific activity towards the mixed micelles of 1-palmitoyl-2-oleoyl-phosphatidylglycerol and cholate was significantly greater in the tumor tissues (6.62 +/- 1.46 nmol/min/mg) than those in the surrounding liver tissues (1.33 +/- 0.22 nmol/min/mg) and controls (0.43 +/- 0.04 nmol/min/mg). The results of immunoblot analysis using a specific anti-human group II PLA2 antibody and of Northern blot analysis using a human group II PLA2 cDNA as a probe demonstrated that group II PLA2 was responsible for the increased enzyme activity. The contents of immunoreactive group II PLA2 in the tumor tissues (8.81 +/- 1.24 ng/mg) were significantly higher than those in the surrounding liver tissues (1.74 +/- 0.27 ng/mg); those in the control tissues were below the analytical range of the method used. The group II PLA2 mRNA was also significantly increased in the tumor tissues, compared with that in the surrounding liver tissues, whereas it was not detectable in the controls. This indicates that group II PLA2 in HCC is induced at the pretranslational level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204668     DOI: 10.1016/0925-4439(94)90029-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Group II and IV phospholipase A(2) are produced in human pancreatic cancer cells and influence prognosis.

Authors:  M Kashiwagi; H Friess; W Uhl; P Berberat; M Abou-Shady; M Martignoni; S E Anghelacopoulos; A Zimmermann; M W Büchler
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

2.  Regulation of arachidonic acid, eicosanoid, and phospholipase A2 levels in murine mast cells by recombinant stem cell factor.

Authors:  A N Fonteh; J M Samet; F H Chilton
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

3.  Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.

Authors:  C Gustafson-Svärd; I Lilja; O Hallböök; R Sjödahl
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

4.  Expression of inflammatory secretory phospholipase A2 and cytosolic phospholipase A2 in premalignant and malignant Barrett's oesophagus.

Authors:  Christine Lagorce-Pagès; François Paraf; Dominique Wendum; Antoine Martin; Jean-François Fléjou
Journal:  Virchows Arch       Date:  2004-03-25       Impact factor: 4.064

Review 5.  Targeting the eicosanoid pathway in hepatocellular carcinoma.

Authors:  Anshuli Razdan; Nathan M Main; Vincent Chiu; Nicholas A Shackel; Paul de Souza; Katherine Bryant; Kieran F Scott
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  Lipids, curvature, and nano-medicine.

Authors:  Ole G Mouritsen
Journal:  Eur J Lipid Sci Technol       Date:  2011-10       Impact factor: 2.679

Review 7.  Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect.

Authors:  Hayley Nehoff; Neha N Parayath; Laura Domanovitch; Sebastien Taurin; Khaled Greish
Journal:  Int J Nanomedicine       Date:  2014-05-22

8.  The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer.

Authors:  Masaya Hiyoshi; Joji Kitayama; Shinsuke Kazama; Yoshitaka Taketomi; Makoto Murakami; Nelson H Tsuno; Kumiko Hongo; Manabu Kaneko; Eiji Sunami; Toshiaki Watanabe
Journal:  Oncol Lett       Date:  2012-12-10       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.